Small-Molecule Inhibitors of the NusB–NusE Protein–Protein Interaction with Antibiotic Activity
Open Access
- 25 July 2017
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 2 (7) , 3839-3857
Abstract
The NusB–NusE protein–protein interaction (PPI) is critical to the formation of stable antitermination complexes required for stable RNA transcription in all bacteria. This PPI is an emerging antibacterial drug target. Pharmacophore-based screening of the mini-Maybridge compound library (56 000 molecules) identified N,N′-[1,4-butanediylbis(oxy-4,1-phenylene)]bis(N-ethyl)urea 1 as a lead of interest. Competitive enzyme-linked immunosorbent assay screening validated 1 as a 20 μM potent inhibitor of NusB–NusE. Four focused compound libraries based on 1, comprising 34 compounds in total were designed, synthesized, and evaluated as NusB–NusE PPI inhibitors. Ten analogues displayed NusB–NusE PPI inhibition ≥50% at 25 μM concentration in vitro. In contrast to representative Gram-negative Escherichia coli and Gram-positive Bacillus subtilis species, these analogues showed up to 100% growth inhibition at 200 μM. 2-((Z)-4-(((Z)-4-(4-((E)-(Carbamimidoylimino)methyl)phenoxy)but-2-en-1-yl)oxy)benzylidene)hydrazine-1-carboximidamide 22 showed excellent activity against important pathogens. With minimum inhibitory concentration values of ≤3 μg/mL for Gram-positive Streptococcus pneumoniae and methicillin-resistant Staphylococcus aureus and ≤51 μg/mL for Gram-negative Pseudomonas aeruginosa and Acinetobacter baumannii, 22 is a potent lead for a novel antibacterial target. Epifluorescence studies in live bacteria were consistent with 22, inhibiting the NusB–NusE PPI as proposed.Keywords
Funding Information
- National Health and Medical Research Council
- Australian Cancer Research Foundation
- Australian Research Council
- Ramaciotti Foundations
- University of Newcastle Australia
This publication has 43 references indexed in Scilit:
- Attenuating Staphylococcus aureus Virulence Gene Regulation: A Medicinal Chemistry PerspectiveJournal of Medicinal Chemistry, 2013
- Variability in docking success rates due to dataset preparationJournal of Computer-Aided Molecular Design, 2012
- Structural basis for RNA recognition by NusB and NusE in the initiation of transcription antiterminationNucleic Acids Research, 2011
- The 10 × ‘20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020Clinical Infectious Diseases, 2010
- Rationalizing the chemical space of protein–protein interaction inhibitorsDrug Discovery Today, 2010
- Activity of a New Antipseudomonal Cephalosporin, CXA-101 (FR264205), against Carbapenem-Resistant and Multidrug-Resistant Pseudomonas aeruginosa Clinical StrainsAntimicrobial Agents and Chemotherapy, 2010
- Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2009
- Structural and Functional Analysis of the E. coli NusB-S10 Transcription Antitermination ComplexMolecular Cell, 2008
- Structural Biophysics of the NusB:NusE Antitermination ComplexJournal of Molecular Biology, 2008
- Small-molecule inhibitors of protein–protein interactions: progressing towards the dreamNature Reviews Drug Discovery, 2004